{"entity":{"id":"ryvu-therapeutics","kind":"company","name":"Ryvu Therapeutics","aka":["Ryvu Therapeutics SA"],"tldr":"Ryvu Therapeutics is a Poland-based biotechnology company running 5 late-stage cancer trials of RVU120, MEN1703 and Glofitamab in acute myeloid leukaemia, myelodysplastic syndromes / neoplasms and hodgkin lymphoma.","summary":"Ryvu Therapeutics, based in Krakow, Poland, is a biotechnology company. A clinical-stage drug discovery and development company focused on novel small-molecule therapies addressing emerging targets in oncology. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials, testing RVU120, MEN1703, Glofitamab and Ruxolitinib in acute myeloid leukaemia, myelodysplastic syndromes / neoplasms, hodgkin lymphoma and myeloproliferative neoplasms. The largest, NCT06397313 (RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis), plans to enrol 230 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.ryvu.com"},{"label":"ClinicalTrials.gov: trials led by Ryvu Therapeutics","url":"https://clinicaltrials.gov/search?lead=Ryvu%20Therapeutics%20SA"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["aml","mds","hodgkin-lymphoma","myeloproliferative-neoplasms"],"sections":[],"technologies":[],"targets":[],"drugs":["men1703","rvu120"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06534437","nct06243458"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Krakow","country":"PL","companyType":"biotech","website":"https://www.ryvu.com","stage":"public","investors":[],"funding":[]},"route":"/companies/ryvu-therapeutics/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"},{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"drug":[{"id":"men1703","kind":"drug","name":"MEN1703","route":"/drugs/men1703/"},{"id":"rvu120","kind":"drug","name":"RVU120","route":"/drugs/rvu120/"}],"trial":[{"id":"nct06534437","kind":"trial","name":"MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)","route":"/trials/nct06534437/"},{"id":"nct06243458","kind":"trial","name":"RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms","route":"/trials/nct06243458/"},{"id":"nct06191263","kind":"trial","name":"Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML","route":"/trials/nct06191263/"}]}}